The Silicon Review - Best Business Review Magazine Super 30 Companies of the Year 2019 | Page 66

Creating the Largest
Real-World Evidence
Platform for Patients
and Fuels Innovation
Holmusk
Providing a solution for Mental Health - the “Cancer” of tomorrow
M
ental health disorders remain
the highest unmet medical
need, surpassing cardiovascular
disease, diabetes, and cancer. Cumulative
economic burden exceeds 16 Trillion
USD in direct and indirect costs. Holmusk
addresses this problem by building the
world’s largest Real-World Evidence
(RWE) platform for mental health to
deliver clinical and regulatory grade
evidence to all major stakeholders of the
healthcare ecosystem.
The company’s proprietary technology is
also harnessed to analyze real-world data
across other chronic metabolic diseases
including diabetes, cardiovascular
disease, chronic kidney disease, etc.
By integrating the work on metabolic
diseases with the mental health RWE
platform it can generate even deeper
insights. The company’s goal is to develop
a system-wide integrated care model
between mental and chronic health which
makes access to RWE a reality of today,
rather than a dream of tomorrow.
Data Analytics
Holmusk analytics work in the
intersection of pharma& healthcare
practice. It’s model help identify patients
with unmet needs; those who will benefit
most from new interventions, and
provide biological insights to facilitate
new drug research & development.
The company’s Analytics Platform
leverages scientific research, digital
health, and EHR data to inform predictive
algorithms and provide actionable
insights for personalized medicine.
Nawal Roy, Founder & CEO
Statistical analysis of clinical trial data
has been standardized over the years.
With the entry of real-world data
(RWD) from EHRs and data captured
through digital platforms, there is a
need for a new approach. The challenge
of generating validated evidence from
RWD is particularly acute in behavioral